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a b s t r a c t
The ﬁrst alcohol septal ablation (ASA) was performed in 1994. The concept of ‘‘therapeutic
acute myocardial infarction’’ caused by application of concentrated alcohol into coronary
artery is not quite unique since certain arrhythmias were treated in a similar way in the past;
however, ASA has been discussed widely since its introduction and refused for many years
by many cardiologists. Sufﬁciently robust data from long-term follow-up of patients with
hypertrophic obstructive cardiomyopathy treated with ASA were obtained in the past few
years only, demonstrating the safety and long-term efﬁcacy of ASA. This article deals with a
history of the above-mentioned interventional procedure, its indications, technical aspects,
safety, and long-term results.
# 2014 Published by Elsevier Urban & Partner 
Cardiology.
* Correspondence to: Cardiology Clinic of the 2nd Faculty of Medicine and University Hospital Motol, V Úvalu 84, Praha 5 15000, Czech
Republic. Tel.: +420 2 24434900; fax: +420 2 24434920.
E-mail address: josef.veselka@fnmotol.cz
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/crvasa
Sp. z o.o. on behalf of the Czech Society of.http://dx.doi.org/10.1016/j.crvasa.2014.12.004
0010-8650/# 2014 Published by Elsevier Urban & Partner Sp. z o.o. on behalf of he Czech Society of Cardiology.T.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 6 – e 2 7 e17Characteristics of hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common
cardiovascular disorder with a monogenic inheritance, char-
acterized by myocardial hypertrophy without a clear external
cause like hypertension or aortic stenosis [1,2] (Fig. 1). This
deﬁnition is very general and aims to make the diagnosis of
HCM as easy as possible while leaving out the fact that
hypertrophy may be caused by other factors, such as storage of
certain substances in the extracellular space (amyloidosis), or
that it can only involve the basal segment of the interventric-
ular septum like in older hypertonics with sigmoid septum. On
the other hand, it makes the diagnosis easier for cardiologists
despite the fact that it ‘‘pulls together’’ patients suffering from
obviously different disorders.
The genetic background of HCM is extremely heteroge-
neous and the same statement applies to the phenotype of the
disease. Heart morphology may vary greatly, especially
concerning the extent and localization of myocardial hyper-
trophy, anatomy of papillary muscles, length of tendinous
chords and of mitral valve cusps, angle between the root of
aorta and interventricular septum, and presence/extent of
largely ﬁbrotic myocardial foci and of foci consisting of
myocardial disarray. Hypertrophy of the interventricular
septum, longer cusps of the mitral valve, and abnormalities
of papillary muscles are the most common reasons why an
obstruction of the left ventricular outﬂow is seen in about two
thirds of patients [3]. Heterogeneity of the genetic substrate
and of heart morphology is mirrored by the wide range of
clinical manifestations and courses of this cardiomyopathy.
Many individuals with HCM are asymptomatic, the prognosis
of some is similar to that of the general population while other
subgroups have much worse expectations including the risk of
sudden cardiac death or heart failure [4].Fig. 1 – Transthoracic echocardiography, parasternal long
axis view. Typical presentation of severe HOCM with
marked hypertrophy of the interventricular septum and
subaortic obstruction. This obstruction is caused by
anterior movement of the anterior cusp of the mitral valve
and its tendinous chords together with the thickened
interventricular septum.History and nomenclature
Opinions concerning who was the ﬁrst to describe HCM may
vary but most agree that the ﬁrst description was published by
forensic pathologist Teare more than 50 years ago [5]. He was
not sure himself what illness he was describing when being
repeatedly confronted with cardiac hypertrophy in young
victims of sudden death. He thought that cardiac tumors may
have been present. Given the above mentioned heterogeneity
of the heart morphology, many other publications dealing
with the same disorder each used their original name for it.
The nomenclature thus became completely chaotic but
fortunately it was uniﬁed in quite a determined way by other
authors in the 1970s, pursuing the term ‘‘hypertrophic
cardiomyopathy’’. Thanks to professor Gregor, this term was
adopted in the Czech Republic as well and we have no doubt
about what disorder is being discussed when HCM is
mentioned today.
Therapy of hypertrophic cardiomyopathy
Studies dealing with HCM are usually characterized by small
numbers of participants – tens of subjects are typical,
hundreds exceptional, more than thousand represent a rarity.
The number of randomized trials in the history of HCM could
also be counted using the ﬁngers of two hands [6]. This fact –
along with the pronounced morphological and clinical
heterogeneity of the disease – has a profound effect on the
robustness of our knowledge and on the assessment of
effectiveness of our therapeutic approaches, too.
Pharmacotherapy of HCM has not changed nor developed
much since its earlier diagnosis based on echocardiography
ﬁndings. Logically, symptomatic patients are given medica-
tions decreasing the use of oxygen and prolonging the diastole.
We have been doing this for decades using beta blockers and
verapamil. Attempts to decrease the risk of sudden death with
pharmacotherapy have failed; patients who were symptom-
atic despite taking the appropriate medications or at risk of
sudden death were thus offered non-pharmacological thera-
peutic approaches [1,2].
One of the ﬁrst was myectomy, which – especially in its
extensive form – proved to be a very effective therapeutic tool
in the hands of experienced surgical teams, diminishing or
even eliminating the intraventricular obstruction [7,8]. Myec-
tomy is based on excision of several grams of myocardium,
usually protruding from the hypertrophic basal segment of
interventricular septum into the outlet tract of the left
ventricle. The growing body of experience of several surgical
teams in large countries where it was possible to concentrate
patients with HCM has led to improvements in the surgical
technique and widening of the originally small myotomy, then
excision and eventually plastic of the papillary muscles and
the entire mitral apparatus. Good surgical results were
followed by publications describing elimination of intraven-
tricular obstruction, further decrease of left ventricular
hypertrophy and marked reduction in symptoms [9]. One
problem concerning myectomy has not been solved until now,
namely the relative complexity of the entire procedure and the
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surgeon. This means that countries with less potential surgical
candidates usually lack a cardiosurgical team sufﬁciently
acquainted with this operation. The current political/econom-
ical interconnection among various European countries did
not change much in this respect. In one of our multicentre
study publications, reﬂecting the contributions of HCM centers
from the Czech Republic, Germany, Austria, Poland, Slovakia,
and Bulgaria, we demonstrated 14% early mortality following
myectomy [10]. These data are sadly different from those
published by major American centers, in which the mortality
rate following myectomy was close to zero [9]. However, we
can expect that all of the published results are true and that
they reﬂect the clinical practice and experience in different
parts of the world. This may be the reason why American
guidelines concerning HCM, formulated by authors mainly
from ‘‘surgically oriented centers’’, present myectomy as a
procedure of choice in severely symptomatic patients suffer-
ing from the obstructive form of HCM (HOCM) [1]. In the Central
Europe, however, the procedure of choice is ASA despite the
undisputed studies from large North American centers [4,11].
History of alcohol septal ablation
Alcohol septal ablation (ASA) is an alternative therapeutic
procedure leading to elimination of HOCM symptoms. The
history of this intervention is extremely interesting and
provides many pieces of information that can be generalized
with respect to the development of the entire cardiology.
The primacy concerning the procedure itself is not disputed
by many. The ﬁrst procedures were performed by Ulrich
Sigwart and his coworkers in London in June 1994 and they
were published in the Lancet a year later [12]. Uncertainties
remain as to how and when Sigwart developed the entire
concept of myocardium ablation using alcohol. The most cited
version of Sigwart himself says that he had observed the
decrease of intraventricular obstruction following inﬂation of
the balloon catheter in the septal branch supplying the basal
segment of interventricular septum as early as 10 years prior to
the ﬁrst ASA. However, this decrease of the gradient was only
temporary and the gradient returned back to the initial value
within tens of minutes, possibly based on the collateral
circulation in the septum. This made Sigwart to contemplate
not just ischemization but necrotization of the myocardium
that could lead to permanent gradient decrease. Ethical
committee did not approve of this procedure, however, so
Sigwart had to wait for the next 10 years for the London period
of his career, during which ASA became already possible.
According to the less frequently cited version concerning to
the ASA concept development, the procedure was being
prepared for several years in Bielefeld and a poster was
presented at the conference of German Cardiologic Society in
April 1994, describing the decrease of the gradient after the
inﬂation of balloon catheter in the ﬁrst septal branch along
with the planned intraseptal alcohol application. Two months
later, the procedure was performed by Sigwart in London
[13,14]. As Sigwart's critics also pointed out, the references to
publications that inspired him allegedly to develop ASA do not
contain any information about alcohol or HOCM patients [13].On the other hand, alcohol was used shortly before the ﬁrst
ASA by the Brugada group for ablations of ventricular
arrhythmias, which step may have inspired interventional
cardiologists, too [15].
After the ﬁrst three case studies describing ASA were
published (under Sigwart's title ‘‘Non-surgical Myocardial
Reduction for Hypertrophic Obstructive Cardiomyopathy’’),
passionate discussions appeared in the Lancet, concerning the
justiﬁcation of ASA, its ethical aspects and especially the
prognosis of patients undergoing this intervention [16,17].
Sigwart was criticized by his London colleagues who saw the
ablation as ‘‘an uncontrolled maneuver on the totality of left
ventricular function leading to further left ventricular failure’’.
Sigwart opposed them with a prophetic statement: ‘‘Dimin-
ishing the outﬂow tract gradient in patients with symptoms
may greatly improve quality of life and reduce symptoms.
There is not the slightest evidence that this procedure will lead
to acceleration of left ventricular failure’’ [17]. This statement
was brave and wise and it proved to be true within the
following two decades.
In the Czech Republic, the ﬁrst ASA was performed at the
Department of Internal Medicine Clinic of the University
Hospital Motol by associate professor Hlaváček with the
assistance of professor Kuhn in the spring 1998. Several
months later, ASA was also performed by us and by the group
of Dr. Januška as we described later in Cor et Vasa [18].
Indications of alcohol septal ablation
Indications of ASA are very similar now to those deﬁned at the
beginning of the millennium; in the clinical practice, however,
their modiﬁcations are based on the experience with the
procedure, current positive or negative references about its
effects and, last but not least, on the guidelines, which have
their legal consequences – especially in the developed world.
We always limit the indication of ASA to severely
symptomatic patients who consider themselves to be marked-
ly limited in their everyday life [1]. The question is whether we
would deny this procedure to a younger patient suffering from
NYHA class II symptoms; would we strictly adhere to the
guidelines, allowing the elimination of obstruction only in
patients with NYHA class III symptoms? I personally prefer to
respect the choice made by the patient after carefully
explaining the effects of the method and the risks associated
with its use.
It is generally accepted that the patient should have a
subaortic pressure gradient above 30 mmHg (maximal gradi-
ent measured by continuous Doppler echocardiography in
horizontal position). Some cardiologists respect European
recommendation of a gradient exceeding 50 mmHg [1,2,19–
21]. It should be noted that these thresholds are not based on
the evidence in the literature dealing with HOCM but
represent a mere consensus of experts, the only exception
being the conﬁrmation of 30 mmHg as a threshold for the risk
of future death and heart failure [22]. It is well known,
however, that the variability of intraventricular obstruction
across days is extremely high and that an incorrect diagnosis
of obstruction corresponding to >30 mmHg can be made in
about one ﬁfth of patients based on a single measurement
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when it comes to provoked obstruction. Moreover, the
provocation of gradient is not strictly standardized. We use
sublingual application of a spray containing isosorbide
dinitrate. It was shown by us that its effectiveness can be
increased by its combination with Valsalva maneuver and
especially by waiting for at least 10 min between the
application and measurement [3]. Another possibility
approaching the gold standard is represented by measuring
the gradient in association with physical activity. This
approach has its caveats, too. Changing the patient's position
from vertical to horizontal immediately after the physical
activity may increase the preload and thus lead to partial
reduction in the gradient. On the other hand, vertical position
– so typical of our everyday life – is associated with limited
applicability of transthoracic echocardiography [24].
The gradient may alternatively be provoked by application
of positive inotropic substances, typically dobutamine. I
consider this test rather non-physiological myself since it
does not correspond to any situation usually encountered by
the patient in his/her everyday life but under certain
circumstances – in cases of discrepancy between echocardio-
graphic ﬁndings obtained at rest and marked symptomatology
– it can be accepted as an accessory evaluation.
The width of interventricular septum necessary for an
indication of ASA represents another debatable parameter.
Individual recommendations vary between 15 and 18 mm and,
interestingly, this again is a mere consensus not based on any
robust data [1,2,19–21]. Extremely rare published cases of ASA-
induced ventricular septum defects were also never associated
with a small width of the target segment of interventricular
septum [19–21,25,26].
The subaortic gradient depends to a varying extent on the
function of mitral valve and submitral apparatus. As shown by
studies using magnetic resonance, both mitral leaﬂets are
usually prolonged in HOCM patients [27]. In cases where
redundant tendinous chords or hypertrophic papillary mus-
cles are also present, it becomes clear that these factors can
have much more profound inﬂuence on the subaortic or
midventricular obstruction than a slightly thickened inter-
ventricular septum. It has to be pointed out that these factors
are neglected by virtually all authors commenting on the ASA
indications despite the fact that they can be crucial for the
indication of optimal non-pharmacological treatment. It
would be logical if such a patient would undergo not only
myectomy but also repair of mitral valve and submitral
apparatus including the papillary muscles. In clinical practice,
absence of experienced cardiac surgeons, who would be
capable of learning to perform such an operation in countries
comparable in size to the Czech Republic and to keep the
experience through adequate number of procedures per-
formed, is the most important obstacle.
In the past, reassuring reports of ASA proponents were
published, describing the possibility to use this technique even
in patients with midventricular obstruction or even apical
hypertrophy [28,29]. Personally, I am sceptical with respect to
these procedures. When we look at the pathophysiological
basis of the given clinical presentations, we must conclude
logically that the predicted extent of ablation involving
the papillary muscles – that are usually responsible formidventricular obstruction – is impossible in principle.
Moreover, midventricular obstruction is usually caused not
only by hypertrophy of the papillary muscles but also by their
anteroapical displacement, redundancy concerning the num-
ber of papillary muscle heads or muscles themselves, and also
by missing or markedly shortened tendinous chords, in which
situation the muscle usually inserts partially or fully to the
mitral valve itself. This complex anatomical change can hardly
be compensated for by ASA, leading to mere thinning of
myocardium in the basal or middle segment of the interven-
tricular septum.
Since right bundle branch block occurs in about one half of
patients who underwent ASA, we consider left bundle branch
block a relative contraindication of ASA [25,26]. Myectomy, on
the other hand, often leads to left bundle branch block;
preoperative right bundle branch block is thus associated with
a high risk of postoperative trifascicular block.
Technical aspects of alcohol septal ablation
When following the development of ASA technique, we must
bear in mind that despite personal communications of certain
pioneers of this procedure there is no serious animal model
which would help to optimize its performance. Thus, the ﬁrst
ASAs were described, due to the absence of above mentioned
preliminary studies, as clinical experiments without any
exaggeration. Interventional cardiologists made haste to
implement the new method and its technique was being
reﬁned through errors and successes. It has to be stressed that
such an approach is far from speciﬁc for ASA in interventional
cardiology; clinical experimenters with stem cells acted in a
similar manner during the same time period.
Several questions had to be answered concerning the ASA
technique. The optimal alcohol dose with respect to the
effectiveness of the procedure (obstruction decrease) and
long-term safety (minimal extent of the ensuing scar as a
potential arrhythmogenic substrate) was one of the most
important ones. Initial alcohol doses were up to 11 ml [30],
with a tendency to decrease the alcohol dose gradually to
1–3 ml of 96% alcohol [1,2]. Low alcohol doses were advocated
especially by Kuhn who abandoned 1–2 ml doses (‘‘low dose’’)
for less than 1 ml doses (‘‘ultra-low dose’’) [31,32]. Finding
these less effective, he returned to recommending 1–2 ml
doses. Our group also contributed to the discussion about
optimal dose of alcohol since we published several articles
describing outcomes in patients randomized to low or
classical alcohol dose [33–38]. We have shown that some
1.5 ml of alcohol lead to the desired pressure gradient
decrease by about 70–80% while maintaining the long-term
safety for patients [35]. We thus supported the generally
accepted recommendation to use low alcohol doses during
ASA, eventually endorsed by most of the authors publishing
articles on this topic [1]. Recently, we have shown that alcohol
doses lower than 1 ml are already associated with less
effectiveness of the procedure [10]. There is an interesting
rule concerning the planning of alcohol dose, used by other
proponents of this method originally working in Bad
Oyenhausen: according to this rule, the number of milliliters
of alcohol applied should correspond to the width of the target
Fig. 2 – Coronary angiography of the left coronary artery in right anterior oblique projection. The septal artery (a) is closed
following the application of alcohol (b).
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 6 – e 2 7e20interventricular septum in centimeters. In most cases,
application of alcohol to the septal branch leads to its
immediate closure (Fig. 2) and to marked reduction or
elimination of the pressure gradient in about two thirds of
patients (Fig. 3).
Detection of the optimal target artery to which alcohol
should be applied represented a similarly important question
[39]. Initial approach consisted of application of alcohol to theFig. 3 – Pressure gradient between the left ventﬁrst septal branch; according to the basic recommendation,
the procedure should be completed when the gradient had
decreased already after the inﬂation of balloon catheter in the
artery, causing ischemia of the target segment of the
interventricular septum [13]. Kuhn and others have been
developing and using this strategy throughout the history of
ASA. Absolute majority of interventional cardiologists, how-
ever, use myocardial contrast echocardiography for detectionricle and aorta before (a) and after ASA (b).
Fig. 4 – Coronary angiography and transthoracic echocardiography in apical projections with intraseptal application of echo
contrast medium enabling the identification of the given septal branch territory. This is the first examination performed by
Prof. Faber in 1996. Published with permission of the author.
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amount of echo contrast medium to the potentially target
artery. After this, they follow the size and localization of the
to-be-ablated focus (using transthoracic echocardiography or –
exceptionally – some modiﬁcations of transthoracic echocar-
diography or intracardiac echocardiography) along with
possible leak of the echo contrast medium to segments not
involved in the development of intraventricular obstruction
[30,40]. This technique has been gradually modiﬁed to an
extent throughout the years [41] but typically, it is still used
today as it was developed at the end of the nineties. Although
the ﬁrst larger study concerning this topic was published by
investigators from Houston in the October issue of Circulation
in 1998 [40], the group of Seggewiss and Faber from Bad
Oyenhausen presented a poster on this at a local meeting as
early as two years previously [42] (Fig. 4). These researchers
had a larger group of patients with short-term results
published in Circulation two months after the publication of
their American colleagues [30]. It thus seems that the German
group was the ﬁrst worldwide while the American group from
Houston was the ﬁrst in America. It is interesting for a reader of
current literature that it will become increasingly moredifﬁcult to deﬁne who was the ﬁrst inventor in the current
world of shared information.
As gradually shown by two decades of experience with
ASA, not even myocardial contrast echocardiography is a fully
reliable method always capable of guiding the search for an
optimal artery to ablate. In apical echocardiographic projec-
tions, any contrast-rich focus represents an impenetrable
ultrasound shadow interfering with a reliable detection of its
size and borders (Fig. 5). This obstacle can be obviated, to an
extent, by use of echocardiographic options speciﬁcally
developed for myocardial contrast echocardiography and
thus much more accurate and sensitive when it comes to
detection and deﬁnition of borders of an echo-contrast focus
(real-time myocardial contrast echocardiography) [41] (Fig. 6).
Using this approach, the optimal artery for ablation can be
searched for even at the level of secondary branches of the
septal branch.
Another technical aspect concerns the invasiveness of the
entire procedure when considering the number of vascular
access sites. I have been using two standard arterial access
sites for years, allowing for both measurement of the pressure
gradient and for the intracoronary procedure itself. Some
Fig. 5 – Transthoracic echocardiography, apical projection.
Myocardial contrast echocardiography with a contrast-
enhancing focus in the basal segment of the hypertrophic
interventricular septum. The contrast-enhancing focus
creates an ultrasound shadow interfering with precise
identification of its borders and thus its real size and
location.
Fig. 6 – Transthoracic echocardiography, apical projection.
Myocardial contrast echocardiography with a program for
echo contrast media use (power Doppler).
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pressure gradient by Doppler echocardiography only. More-
over, when the radial access is used, the patient may move to
an extent even immediately following the procedure. It has to
be added here that another invasive access is necessary for
introduction of pacing lead into the right ventricle, because
intra- or post-procedural complete heart block can occur.
Although this text refers to ASA, it is prudent to mention its
alternatives, also characterized by necrosis of the target basal
segment of interventricular septum achieved by substances
other than alcohol. The main reason for developing alternative
methods consisted of the fact that some patients do not have
just one septal artery optimal for ablation but instead, several
submillimeter septal branches hardly distinguishable by
ﬂuoroscopic imaging are present in them, not accessible to
the necessary armamentarium. The situation is similar in
cases when the septal branch supplies the free wall of the left
ventricle (most often, the inferior), the papillary muscles or the
right ventricle structures. Various ASA alternatives have been
proposed for these patients. Initially, implantation of a stent
graft covering the origin of the septal branch became available,
causing a small necrosis in the desired area [43]. It came out,
however, that fast development of collateral circulation lead to
a speedy restitution of the obstruction. Other potential risks
are related to intracoronary implantation of the stent graft,
especially thrombosis and restenosis. An attempt was made to
replace ASA by application of polyvinylalcohol foam instead of
alcohol, which procedure also leads to necrosis and maypotentially lower the risk of alcohol penetration to unsuitable
regions [44]. Not even this method, however, came to wide use.
The same is true for glue application (‘‘glue septal ablation’’)
[45]. Intraseptal thrombosis was set as a goal by authors of a
modiﬁcation consisting of embolization of the septal branch
using coils or even parts of used coronary wires like in the
developing world [46]. The truth is that this approach could be
of use in cases of fully functional collateral circulation through
which alcohol can be driven to remote parts of the myocardi-
um. We have shown that this risk is relevant especially in
patients who underwent ASA already in the past and in whom
the interventional cardiologist wishes to make its effect even
more pronounced by applying another dose of alcohol [47].
Closed microcirculation in the territory of ablated septal
branch causes a marked resistance against another alcohol
dose and opening of collaterals that can drive alcohol back to
the left anterior descending coronary artery via the second
septal artery, with a danger of possible fatal consequences.
Alternatively, ASA can be replaced by endocardial radio-
frequency ablation of the septum, i.e. of a modiﬁed procedure
well known to interventional arrhythmologists [48,49]. This
procedure was ﬁrst proposed and performed by Lawrenz et al.
[49]. Technical difﬁculties concerning the search for optimal
and stable placement of ablation catheter in the left ventricu-
lar outﬂow tract – where it has to be counted on turbulent
blood ﬂow the speed of which usually exceeds 3 m per second –
represents a clear drawback of this approach. Ablations of the
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temporarily for that reason but the effectiveness of this
procedure was limited. Sufﬁciently deep penetration of
radiofrequency energy causing the myocardial necrosis is
also problematic. On the other hand, the possibility to monitor
the conduction system damage represents a clear advantage,
allowing for immediate stopping of the ablation in cases of
atrioventricular block occurrence [48]. This method could
possibly be suitable even for patients without sufﬁcient
thickness of the septal artery, interfering with any interven-
tion on this artery. We were the second group worldwide to use
this method in a patient after ASA in whom the obstruction
recurred [48].
Course of hospitalization after alcohol septal
ablation
The course and length of hospitalization after ASA – like after
myocardial infarctions – depend on the presence of complica-
tions. During the procedure itself, part of the patients develop
a complete heart block (trifascicular block) necessitating a
temporary or permanent cardiac pacing [25,26]. This is the
most common serious complication of the procedure, the rate
of which has decreased to about 20% when using small doses
of alcohol and applying it very slowly. About one half of them
(10%) require permanent pacemaker implantation later [25,26].
According to our estimate, cardiac pacing is still necessary in
about one third of primarily paced patients in the long-term
follow-up [50]. However, the development of complete heart
block is very hard to predict; it can occur repeatedly during one
hospitalization, even days after ASA [25,26,37,50–56]. Recently,
it has been demonstrated that 96% of complete heart blocks
occurred within 5 days of ASA; the minimal length of hospital
stay should hence correspond to this minimal time interval
[25]. Interestingly, the usual length of hospitalization in the U.
S. does not exceed three days. Malignant arrhythmias
requiring immediate electrical cardioversion/deﬁbrillation
may represent another signiﬁcant complication. In our
experience, they occur in 2–4% of patients, typically very early
after the procedure [25,26,57–59]. They resemble primary
ventricular ﬁbrillation episodes in patients with acute myo-
cardial infarction in this respect. Other complications of ASA
are rare to exceptional and they are similar to complications of
other interventions, ranging from major bleeding at the
arterial access site or dissection of the coronary artery to
perforation of the right-heart chambers during placement of a
temporary pacemaker into the right ventricle. Alcohol leak to
the coronary artery or occurrence of interventricular septum
defect may be described as a rare complication as well. As
opposed to the ﬁrst decade after introduction of ASA into
clinical practice, I believe now that periprocedural mortality
related to ASA should not exceed 1% in experienced centers
[19–21,25,26].
Efﬁcacy of alcohol septal ablation
Injection of alcohol is immediately followed by steep decrease
of the pressure gradient between the left ventricle and aorta.This decrease is caused by development of akinesia of the
basal segment of the interventricular septum accompanied by
widening of the left ventricular outﬂow tract during the systole
in the ﬁrst place. The gradient redevelops within hours to days
because of local edema and partial reoccurrence of movement
of the given segment [60,61]. We thus suppose that the steep
decrease of the gradient is caused by necrosis, stunning of the
adjacent myocardium and temporary drop in the contractility
of the left ventricle. This process is later replaced by left
ventricular remodeling, characterized by slow decrease of the
gradient because of interventricular septum thinning (shrink-
ing), mild left ventricle dilation and regression of left ventricle
hypertrophy thanks to afterload decrease (Fig. 7). Although the
ablation itself is associated with loss of several grams of the
myocardium (like myectomy), the weight of the left ventricle
decreases by tens to one hundred of grams during the ﬁrst year
after ASA [62]. Among other things, this fact shows that
hypertrophy in HOCM is not only caused by the disease itself
but also by the obstruction. We ﬁrst described the above model
of pressure gradient changes following ASA in 2004, referring
to it as to biphasic course of the pressure gradient following
ASA [60]. Two years later, an almost identical graph was
published in the American Journal of Cardiology by a group
from Harvard stating that their results were unique [61].
Although attempts were made to explain the coincidental
similarity of the data [63], I believe – when looking years ago –
that this event is fully compatible with the entire history of
ASA.
Age is a very important factor inﬂuencing the morphology
of the left ventricle in HOCM patients. As shown by several
studies, early clinical manifestation of the disease is associat-
ed not only with a positive genotype causing mutations in
sarcomeric proteins but also with an unfavorable course of the
disease itself [64–67]. Younger patients usually suffer from
more pronounced hypertrophy, typically affecting the entire
interventricular septum, which thus protrudes into the left
ventricle and is responsible for its slit-like shape. This fact is
likely also behind our ﬁnding that older patients are more
likely to have a sigmoid septum (with only the basal segment
of the interventricular septum being thickened) and tend to
show a steeper decrease of the pressure gradient following
ASA [68]. This gradient thus reaches its stable and low values
within a single month while in patients younger than 50 years
this decrease typically takes up to 3 months [66]. On the other
hand, we have also demonstrated that patients with the
sigmoid septum morphology had a lower resting pressure
gradient but that their gradient reached the same values after
provocation as in neutral septum morphology; both gradients
could be lowered to comparable values using ASA [68].
Beside the drop in the pressure gradient and left ventricle
weight, many authors have published their ﬁndings concern-
ing other changes of cardiac function. These were related to
various parameters of the diastolic function as well as to the
left ventricular performance [69–72]. To an extent, we have to
be critical when assessing the results of such studies since
they were published mostly by proponents of the method;
besides, it is quite difﬁcult to evaluate the parameters of
diastolic function independently of simple pressure gradient
lowering effects in cases of left ventricular hypertrophy.
However, the gradual regression of the left ventricular
Fig. 7 – Transthoracic echocardiography, parasternal long axis view. Left ventricular remodeling following ASA with thinning
of the basal segment of the interventricular septum during both the diastole (a) and systole (b) without any subaortic
obstruction.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 6 – e 2 7e24hypertrophy, mild dilation of the left ventricle and lowering of
the afterload all have a positive effect on the left ventricular
compliance and relaxation, too [69–73].
When evaluating the effectiveness of any therapeutic
method, it is crucial to assess its effect on the patients'
symptomatology. With respect to this, it has been clear since
the introduction of ASA that this procedure alleviated all the
symptoms like dyspnea, angina (considering both the rate and
intensity), and syncope. The mean decrease of dyspnea
described in the literature corresponds to about 1.5 NYHA
classes, being present in some 90% of patients. About one half
of the patients suffers from NYHA class I dyspnea following
the procedure [31–37,73,74]. Beside these subjective parame-
ters, improvement of VO2max during exercise was documen-
ted as well [75].
Until recently, the critics of ASA mostly pointed to the
prognosis of patients who underwent the procedure [76,77].
The logical argument against the method consisted of the fact
that creation of necrosis produces an increase in the
arrhythmogenic potential in patients with HOCM, disorder
associated a priori with a certain risk of sudden death.
However, three studies were published by different groups
lately (Mayo Clinic, Bad Oyenhausen plus Copenhagen, and
Prague-Motol plus Brno-St. Anna), documenting an excellent
long-term prognosis of patients following ASA [74,78,79]. As
shown by all three groups, the prognosis of ASA patients was
the same as that of general population while the study from
Mayo Clinic described a favorable prognosis following ASAcompared to even that after myectomy [78]. Sudden death was
found to be rare following ASA, the most common cause of
death being a stroke [74]. This fact is probably related to the
occurrence of paroxysmal atrial ﬁbrillation and of left
ventricular diastolic dysfunction as main pathophysiological
factors inﬂuencing the cerebrovascular accident rate. Al-
though we still have to look at the three studies with median
follow-up of 5–8 years with a certain amount of uncertainty,
since increased mortality may only show after longer follow-
up, it is still likely that these studies will change the opinion
concerning ASA – especially behind the Atlantic Ocean where
myectomy remains the preferred approach to the treatment of
obstruction. Positive news concerning the long-term prognosis
of patients following ASA were published by other centers, too
[31,80–82]. According to our recent data, the good prognosis
pertains even to patients who required permanent pacemaker
implantation early after ASA [50].
However, recently published results should not be auto-
matically transfer to the clinical practice without respect to
other factors inﬂuencing the long-term effectiveness of the
procedure. According to the prevailing consensus, centers
performing ASA should specialize in HOCM, should be able to
offer all the alternative treatment methods, and should follow
the patients on a long-term basis; any physician performing
ASA should have an experience corresponding to 20 ASA under
direct leadership of his supervisor [1,4]. To my knowledge, only
3 centers in the Czech republic conform to these criteria. Even
my personal experience suggests that we tend to recommend
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 6 – e 2 7 e25ASA to patients with high gradient, yet completely or almost
asymptomatic, even at centers with little experience concern-
ing both HOCM and ASA.
Prediction of the outcome following ASA in an individual
patient is not easy. It depends on the septal branches
morphology, on the extent of hypertrophy and on the
presence of other abnormalities and pathologies concerning
the papillary muscles and the entire mitral apparatus. It
seems that the outcomes are worse in patients with thicker
interventricular septum and severe diastolic dysfunction. On
the other hand, higher age and less obstruction are the
predictors of good ﬁnal outcome [82,83]. In some patients, the
nature of HOCM may be progressive and elimination of the
obstruction itself may lead just to temporary alleviation of
HOCM symptomatology.
Conclusion
During the two decades of its use, ASA has gone through an
interesting development. Many discussions have been led
about various primacies in its reﬁnement. The introduction of
ASA into clinical practice was not preceded by any robust
studies using animal models that would show what technique
is optimal for the given procedure and what long-term results
can be expected. The ﬁrst publications of Sigwart, Kuhn,
Spencer, Faber, and some others can thus be described as truly
pioneering. In smaller countries where there is no experienced
team of cardiac surgeons capable of performing myectomies
with a mortality below 1% in low-risk patients, ASA offers an
important help to symptomatic patients with HOCM.
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